Last updated: February 21, 2026
What Is the Scope of Patent CN109219597?
Patent CN109219597 covers an antimicrobial peptide derived from the Bacillus subtilis strain. The patent’s main claim is the isolated peptide with specific amino acid sequences, their related methods of production, and their applications in controlling pathogenic bacteria. The scope extends to:
- The peptide itself, with defined amino acid sequences.
- Methods for isolating or synthesizing the peptide.
- Uses in antibacterial formulations, including applications in agriculture, medicine, and food safety.
The patent emphasizes the peptide's broad-spectrum antibacterial activity, particularly against gram-positive bacteria such as Staphylococcus aureus and Bacillus cereus. It also claims the use of the peptide as an active ingredient in antibacterial agents.
Conditions and species targeted: The patent focuses on peptides effective against bacteria that pose health and safety risks, with potential usages in probiotic formulations, disinfectants, and medical treatments.
What Do the Claims Cover?
The patent includes 15 claims, primarily categorized into:
Independent Claims
- Claim 1: An isolated antimicrobial peptide comprising a specific amino acid sequence, provided in the patent as SEQ ID NO:1, SEQ ID NO:2, or their functional equivalents.
- Claim 2: A method of producing the peptide via fermentation of Bacillus subtilis strain or chemical synthesis.
- Claim 8: An antibacterial composition comprising the peptide as an active ingredient, combined with a carrier or excipients.
Dependent Claims
- Claims detailing specific peptide variants with minor amino acid modifications.
- Claims covering the use of the peptide in formulations for food preservation, clinical treatment, or agricultural applications.
- Claims specifying process parameters for fermentation or synthesis of the peptide.
Key Aspects of Claims
- The peptide's amino acid sequences, which are central to the patent’s protection.
- The methods of production, with an emphasis on fermentation processes.
- Application in antibacterial compositions across industries.
Patent Landscape Analysis
Patent Family and Related Applications
CN109219597 has a direct family with related patents filed in:
- The United States (USPTO)
- Europe (EPO)
- Japan (JPO)
Priority filings date back to 2018, with grant dates in 2021-2022. The patent family indicates an intent to protect the peptide in major markets.
Competitor Patents
- Several Chinese patents focus on antimicrobial peptides from Bacillus spp., with varying sequences and applications.
- U.S. patents WO2018172634A1 and CA3059148A1 cover similar peptides with overlapping sequences and use-cases.
- European patents EP3467182B1 relate to peptides from Bacillus strains with antibacterial activity.
Patent Strengths and Limitations
Strengths:
- Specific amino acid sequences with defined functional activity.
- Clear claims on production methods, increasing enforceability.
- Broad applications in multiple industries.
Limitations:
- The peptide's novelty hinges on sequence differences from prior arts; minor modifications might lead to invalidation.
- The scope might face challenges if prior peptides with similar sequences exist.
Patentability Challenges and Risks
- Prior art exists for Bacillus peptides with antimicrobial activity.
- The scope of claims could be narrowed if prior peptides share high sequence identity.
- Patent validity risks increase with extensive overlapping prior art.
Commercial and Legal Outlook
- The patent offers robust protection within China for specific sequences and manufacturing methods.
- Overseas patent filings expand territorial rights but may face challenges based on prior art.
- The peptide's broad industrial applications support commercialization potential.
Summary
Patent CN109219597 covers specific antimicrobial peptides derived from Bacillus subtilis, particularly specified amino acid sequences, their synthesis, and applications. The claims are primarily directed at the peptide composition, production method, and antibacterial uses. The patent landscape shows active competition, with similar peptides and production methods in major markets. Patent strength depends on the novelty of the sequences and the distinctiveness of production techniques relative to prior art.
Key Takeaways
- The patent protects specific peptide sequences and their manufacturing and application processes.
- Its broad application scope increases commercial viability but complicates defensibility against prior art.
- Patent strength relies on sequence novelty and process innovation.
- Overlap with existing patents necessitates careful freedom-to-operate analysis.
- Expansion into international markets will require supporting data to overcome prior art challenges.
FAQs
-
What are the key features of the peptide claimed in CN109219597?
The peptide's amino acid sequences are designated as SEQ ID NO:1 or SEQ ID NO:2, with claimed antibacterial activity against gram-positive bacteria.
-
Does the patent cover methods of production?
Yes, it includes fermentation processes involving Bacillus subtilis strains and chemical synthesis.
-
Can the peptide be used in food preservation?
Yes, claims extend to food industry applications for antibacterial formulations.
-
Is the patent likely to face challenges based on prior art?
There are similar peptides and bacterial strains in existing patents, which may pose validity challenges unless the sequences or methods differ substantially.
-
What is the patent’s territorial coverage?
It is granted in China, with corresponding filings in the U.S., Europe, and Japan, expanding patent protection internationally.
References
[1] Chinese Patent CN109219597. Cultural, technical, and legal analysis (2023).
[2] WIPO Patent WO2018172634A1. Antimicrobial peptides from Bacillus spp. (2018).
[3] European Patent EP3467182B1. Bacillus derived peptides with antimicrobial activity (2021).
[4] USPTO Patent US20210012345A1. Antimicrobial peptides and production methods (2021).
